Cargando…

Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study

AIMS: Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Lande, Martijn E, Rama, Rajiv S, Koldenhof, Tim, Arita, Vicente Artola, Nguyen, Bao-Oanh, van Deutekom, Colinda, Weberndorfer, Vanessa, Crijns, Harry J G M, Hemels, Martin E W, Tieleman, Robert G, de Melis, Mirko, Schotten, Ulrich, Linz, Dominik, Van Gelder, Isabelle C, Rienstra, Michiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227656/
https://www.ncbi.nlm.nih.gov/pubmed/36967470
http://dx.doi.org/10.1093/europace/euad058
_version_ 1785050820219240448
author van de Lande, Martijn E
Rama, Rajiv S
Koldenhof, Tim
Arita, Vicente Artola
Nguyen, Bao-Oanh
van Deutekom, Colinda
Weberndorfer, Vanessa
Crijns, Harry J G M
Hemels, Martin E W
Tieleman, Robert G
de Melis, Mirko
Schotten, Ulrich
Linz, Dominik
Van Gelder, Isabelle C
Rienstra, Michiel
author_facet van de Lande, Martijn E
Rama, Rajiv S
Koldenhof, Tim
Arita, Vicente Artola
Nguyen, Bao-Oanh
van Deutekom, Colinda
Weberndorfer, Vanessa
Crijns, Harry J G M
Hemels, Martin E W
Tieleman, Robert G
de Melis, Mirko
Schotten, Ulrich
Linz, Dominik
Van Gelder, Isabelle C
Rienstra, Michiel
author_sort van de Lande, Martijn E
collection PubMed
description AIMS: Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-terminating AF. METHODS AND RESULTS: The Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodelling, and Vascular Destabilization in the Progression of AF study included patients with self-terminating AF who underwent extensive phenotyping at baseline and continuous rhythm monitoring with an implantable loop recorder (ILR). In this subanalysis, ILR data were used to assess the development of AF progression and the diurnal pattern of AF onset: predominant (>80%) nocturnal AF, predominant daytime AF, or mixed AF without a predominant diurnal AF pattern. The median follow-up was 2.2 (1.6–2.8) years. The median age was 66 (59–71) years, and 117 (42%) were women. Predominant nocturnal (n = 40) and daytime (n = 43) AF onset patients had less comorbidities compared to that of mixed (n = 195) AF patients (median 2 vs. 2 vs. 3, respectively, P = 0.012). Diabetes was more common in the mixed group (12% vs. 5% vs. 0%, respectively, P = 0.031), whilst obesity was more frequent in the nocturnal group (38% vs. 12% vs. 27%, respectively, P = 0.028). Progression rates in the nocturnal vs. daytime vs. mixed groups were 5% vs. 5% vs. 24%, respectively (P = 0.013 nocturnal vs. mixed and P = 0.008 daytime vs. mixed group, respectively). CONCLUSION: In self-terminating AF, patients with either predominant nocturnal or daytime onset of AF episodes had less associated comorbidities and less AF progression compared to that of patients with mixed onset of AF. CLINICAL TRIAL REGISTRATION: NCT02726698
format Online
Article
Text
id pubmed-10227656
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102276562023-05-31 Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study van de Lande, Martijn E Rama, Rajiv S Koldenhof, Tim Arita, Vicente Artola Nguyen, Bao-Oanh van Deutekom, Colinda Weberndorfer, Vanessa Crijns, Harry J G M Hemels, Martin E W Tieleman, Robert G de Melis, Mirko Schotten, Ulrich Linz, Dominik Van Gelder, Isabelle C Rienstra, Michiel Europace Clinical Research AIMS: Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-terminating AF. METHODS AND RESULTS: The Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodelling, and Vascular Destabilization in the Progression of AF study included patients with self-terminating AF who underwent extensive phenotyping at baseline and continuous rhythm monitoring with an implantable loop recorder (ILR). In this subanalysis, ILR data were used to assess the development of AF progression and the diurnal pattern of AF onset: predominant (>80%) nocturnal AF, predominant daytime AF, or mixed AF without a predominant diurnal AF pattern. The median follow-up was 2.2 (1.6–2.8) years. The median age was 66 (59–71) years, and 117 (42%) were women. Predominant nocturnal (n = 40) and daytime (n = 43) AF onset patients had less comorbidities compared to that of mixed (n = 195) AF patients (median 2 vs. 2 vs. 3, respectively, P = 0.012). Diabetes was more common in the mixed group (12% vs. 5% vs. 0%, respectively, P = 0.031), whilst obesity was more frequent in the nocturnal group (38% vs. 12% vs. 27%, respectively, P = 0.028). Progression rates in the nocturnal vs. daytime vs. mixed groups were 5% vs. 5% vs. 24%, respectively (P = 0.013 nocturnal vs. mixed and P = 0.008 daytime vs. mixed group, respectively). CONCLUSION: In self-terminating AF, patients with either predominant nocturnal or daytime onset of AF episodes had less associated comorbidities and less AF progression compared to that of patients with mixed onset of AF. CLINICAL TRIAL REGISTRATION: NCT02726698 Oxford University Press 2023-03-27 /pmc/articles/PMC10227656/ /pubmed/36967470 http://dx.doi.org/10.1093/europace/euad058 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research
van de Lande, Martijn E
Rama, Rajiv S
Koldenhof, Tim
Arita, Vicente Artola
Nguyen, Bao-Oanh
van Deutekom, Colinda
Weberndorfer, Vanessa
Crijns, Harry J G M
Hemels, Martin E W
Tieleman, Robert G
de Melis, Mirko
Schotten, Ulrich
Linz, Dominik
Van Gelder, Isabelle C
Rienstra, Michiel
Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
title Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
title_full Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
title_fullStr Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
title_full_unstemmed Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
title_short Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
title_sort time of onset of atrial fibrillation and atrial fibrillation progression data from the race v study
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227656/
https://www.ncbi.nlm.nih.gov/pubmed/36967470
http://dx.doi.org/10.1093/europace/euad058
work_keys_str_mv AT vandelandemartijne timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT ramarajivs timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT koldenhoftim timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT aritavicenteartola timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT nguyenbaooanh timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT vandeutekomcolinda timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT weberndorfervanessa timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT crijnsharryjgm timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT hemelsmartinew timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT tielemanrobertg timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT demelismirko timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT schottenulrich timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT linzdominik timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT vangelderisabellec timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT rienstramichiel timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy
AT timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy